P
arkinson's disease is a progressive neurodegenerative disease that affects dopaminergic neurotransmission, resulting in bradykinesia, rigidity, and rest tremor. After an initial honeymoon period, during which there is a sustained response to dopaminergic treatment, beneficial effects are hampered by levodopainduced motor complications, 1 progressively compromising quality of life. [2] [3] [4] Because levodopa-responsive parkinsonian symptoms are improved by high-frequency stimulation of the subthalamic nucleus, 5, 6 neurostimulation has become an established treatment for advanced Parkinson's disease with medically intractable fluctuations and dyskinesia [7] [8] [9] [10] and has shown long-term efficacy. [11] [12] [13] It is typically used after the disease has been present for 11 to 13 years, 7-10 when quality of life, social adjustment (psychosocial competence), 14 and professional activity are already severely impaired. Neurostimulation improves quality of life, [7] [8] [9] [10] in addition to motor symptoms. Moreover, later in the course of the disease, features unresponsive to dopaminergic treatment often predominate. Therefore, optimizing quality of life during the period when patients have the greatest response to dopaminergic therapy (and therefore neurostimulation as well) should be considered a major goal of current treatment. We hypothesized that neurostimulation improves quality of life at an earlier stage of Parkinson's disease, as suggested by our pilot trial involving patients with early and mild motor complications. 15 In the current study, we randomly assigned patients with Parkinson's disease and a recent onset of motor complications to receive neurostimulation plus medical therapy or medical therapy only. Disease-related quality of life was chosen as the primary outcome, thereby allowing a global assessment of beneficial and adverse effects in a way that subjectively matters to the patient.
ME THODS

PATIENTS
Patients with Parkinson's disease were eligible for the study if they met the following inclusion criteria: an age of 18 to 60 years; disease duration of 4 years or more; a disease severity rating below stage 3 in the on-medication condition, according to the Hoehn and Yahr scale, with scores ranging from 0 to 5 and higher scores indicating more severe disease 16 ; improvement of motor signs of 50% or more with dopaminergic medication, 6 as assessed with the use of the Unified Parkinson's Disease Rating Scale, part III (UPDRS-III; scores range from 0 to 108, with higher scores indicating worse functioning) 17 ; fluctuations or dyskinesia present for 3 years or less; and a score of more than 6 for activities of daily living in the worst condition despite medical treatment, as assessed with the use of the UPDRS-II (scores range from 0 to 52, with higher scores indicating worse functioning), or mild-to-moderate impairment in social and occupational functioning (score of 51 to 80% on the Social and Occupational Functioning Assessment Scale, 18 with scores ranging from 1 to 100 and lower scores indicating worse functioning).
Exclusion criteria were dementia (a score of ≤130 on the Mattis Dementia Rating Scale, 19 with scores ranging from 0 to 144 and higher scores indicating better functioning), major depression with suicidal thoughts (a score of >25 on the Beck Depression Inventory II, 20 with scores ranging from 0 to 63 and higher scores indicating worse functioning), acute psychosis, and any medical or psychological problem that would interfere with the conduction of the study protocol. 21 Patients with a duration of disease of less than 4 years were excluded because atypical forms of parkinsonism would be expected to be identifiable before then. Details regarding the scales are provided in Tables S1, S2 , and S3 in the Supplementary Appendix, available with the full text of this article at NEJM.org.
STUDY DESIGN
Conducted in Germany and France, this study followed an investigator-initiated, randomized, multicenter, parallel-group design comparing neurostimulation plus medical therapy (neurostimulation group) with medical therapy alone (medical-therapy group). Randomization was performed centrally at the University of Marburg coordinating center, Marburg, Germany, with the use of randomization lists with randomly permuted block lengths stratified according to center.
The trial conformed to the Declaration of Helsinki, Good Clinical Practice guidelines, and the International Organization for Standardization 14:155 (2003) standards and was approved by the ethics committee for each participating center.
All patients provided written informed consent before randomization. An independent data and safety monitoring committee provided review and direction regarding the collection of safety data.
Full source-data verification was performed by monitors from the German coordinating center (Koordinierungszentrum für Klinische Studien) for the German centers and by monitors from the French coordinating center (Department of Clinical Research, Assistance Publique-Hôpitaux de Paris) for the French centers. Data were collected and analyzed by the German coordinating center in Marburg. All the authors vouch for the accuracy of the data and the analyses reported and for the adherence of the study to the protocol, available at NEJM.org. The protocol committee designed the study, and the steering committee wrote the first draft of the manuscript. Medtronic provided additional funding for the study but had no role in the study design, data accrual, data analysis, or manuscript preparation.
Patients assigned to neurostimulation underwent bilateral stereotactic surgery of the subthalamic nucleus with the implantation of electrodes (model 3389, Medtronic) and a pulse generator (Kinetra or Soletra, Medtronic) within 6 weeks after randomization, according to operative standards that address local anesthesia, imaging, targeting, microelectrode recording, and confirmation of the final electrode position. 21 Patients in the neurostimulation group then began receiving stimulation according to standards established for this study (see the Supplementary Appendix). 21 Assessments were scheduled at baseline and at 5, 12, and 24 months. A levodopa challenge test was performed at baseline and at 24 months (see the Supplementary Appendix). 21 Blinded assessments were based on preoperative and postoperative standardized video recordings obtained at baseline and at 24 months. Videos were recorded for each motor condition (according to whether the patient was or was not receiving medication or stimulation). The UPDRS-III score was assessed by two expert raters who were unaware of the study assignments, 22 except for the assessment of rigidity, which cannot be evaluated on the basis of a video recording.
During follow-up, adjustments to medication and stimulation were performed according to predefined standards. 21 These standards followed the European Federation of Neurological Societies guidelines for the treatment of advanced Parkinson's disease 23 and a standardized sequence of interventions. 21 An independent expert panel assessed whether medication therapy was consistent with guidelines for each patient (see the Supplementary Appendix).
A specific procedure for monitoring the risk of suicidality, established after two suicides had occurred during the study, consisted of a baseline assessment of the general risk and a semistructured telephone interview every 2 months to assess status, with psychiatric follow-up as needed (see the Supplementary Appendix). 21 
OUTCOME MEASURES
The primary end point was the between-group difference in mean change in quality of life from baseline to 2 years, as assessed with the use of the summary index of the Parkinson's Disease Questionnaire (PDQ-39). 24, 25 After we obtained a significant result for quality of life, the following clinically relevant motor functions were tested sequentially as major secondary outcomes: activities of daily living (UPDRS-II score), 17 severity of motor signs (UPDRS-III score), severity of treatment-related complications (UPDRS-IV score), and time with good mobility and no troublesome dyskinesia, as recorded by patients in a diary. Minor secondary outcomes included scores on the Scales for Outcomes in Parkinson's Disease-Psychosocial (SCOPA-PS) questionnaire (on a scale from 0 to 33, with higher scores indicating worse functioning), the Mattis Dementia Rating Scale 19 (on a scale of 0 to 144, with higher scores indicating better functioning), the Brief Psychiatric Rating Scale 26 (on a scale of 18 to 126, with higher scores indicating worse functioning), the Montgomery and Åsberg Depression Rating Scale 27 (on a scale of 0 to 60, with higher scores indicating worse functioning), the Beck Depression Inventory II 20 (on a scale of 0 to 63, with higher scores indicating worse functioning), and the Starkstein Apathy Scale 28 (on a scale of 0 to 42, with higher scores indicating worse functioning), as well as the levodopa-equivalent daily dose. 7, 9, 21, 29 The other minor secondary outcomes are listed in the Supplementary Appendix.
ADVERSE EVENTS
Adverse events in all patients were reported and coded according to the Medical Dictionary for Regulatory Activities, version 14.1. Serious adverse events were defined as any events that led to death, disability, or prolonged or new hospitalization with serious health impairment.
STATISTICAL ANALYSIS
The sample size was calculated on the basis of our previous studies. 7, 15 We selected a power of 80% for a two-sided Mann-Whitney test, assuming normally distributed data. To detect a standardized effect size of 0.4 with an alpha level of 5%, we calculated that we would need to enroll 208 patients. Assuming a 15% rate of loss to follow-up, we determined that a total enrollment of at least 246 patients would be required. The intention-to-treat analysis was primary; the perprotocol analysis was secondary. No interim analysis was planned. The Mann-Whitney test was replaced by a flexible and robust linear mixed-model analysis with baseline adjustment and included study center as a random effect, main effects for group and time, a group-by-time interaction term, and a generalized covariance matrix to account for serial dependency among observations after verification of the assumption of multivariate normality for the parametric model. 21 Differences in mean changes between assessments at baseline and at 24 months were compared between the groups. Missing data due to loss to follow-up were handled by means of direct likelihood analyses, 30, 31 with adjustment for the conditional expectation of the missing measurements, given the observed ones.
A serial gatekeeper procedure was planned. If the primary end point was significant, the UPDRS-II, UPDRS-III, and UPDRS-IV scores and time with good mobility and no troublesome dyskinesia were tested sequentially with the use of Hochberg's multiple-comparison method 32 at a significance level of 5%.
R E SULT S
CHARACTERISTICS OF THE PATIENTS
Of 392 patients assessed for eligibility, 251 were enrolled between July 2006 and November 2009 at nine German and eight French university centers ( Fig. S1 in the Supplementary Appendix). The intention-to-treat population consisted of 124 patients assigned to the neurostimulation group (120 of whom underwent implantation and completed the study) and 127 patients assigned to the medical-therapy group (of whom 125 underwent medical therapy and 123 completed the study). A total of 25 patients had major protocol deviations, including PDQ-39 assessment outside the predefined time window, an absence of motor fluctuations or dyskinesia, insufficient exposure to treatment, and death during the study period. The per-protocol analysis included 116 patients in the neurostimulation group and 110 in the medical-therapy group (Fig. S1 in the Supplementary Appendix). Baseline characteristics did not differ significantly between the treatment groups ( Table 1 ). The mean duration of Parkinson's disease was 7.5 years, and patients were included in the study a mean of 1.7 years after the onset of levodopa-induced motor complications of any severity.
QUALITY-OF-LIFE, ACTIVITIES OF DAILY LIVING, AND MOTOR OUTCOMES
The primary outcome (PDQ-39 summary index score) was improved from baseline to 24 months by 26% in the neurostimulation group but worsened by 1% in the medical-therapy group (Table 2 ). In the intention-to-treat population, the betweengroup difference in the mean change from baseline was 8.0 points (P = 0.002), which was similar to the between-group differences in the per-protocol population and the group of patients who completed the PDQ-39 assessment. The maximum each end point assuming normally distributed data, with the baseline value for baseline adjustment, main effects for group and time, a group-by-time interaction term, study center as a random effect, and a generalized covariance matrix to account for serial dependency among observations. Reported are the generalized least-squares estimates with standard errors. † P<0.05 for the within-group change.
‡ P values for the major secondary end points were calculated after adjustment for multiple comparisons with the use of Hochberg's method. effect was reached at 5 months and remained stable for up to 24 months (Fig. 1A) . Scores in all domains of the PDQ-39 except for communication and social support showed significant improvement in favor of neurostimulation (Fig. 1B) . The SCOPA-PS score for psychosocial performance was also significantly better in the neurostimulation group than in the medical-therapy group (P = 0.02). These changes were confirmed by further testing with the use of generic and disease-specific quality-of-life and disability scales (Table S3 in the Supplementary Appendix). UPDRS-III scores for the severity of parkinsonian motor signs in the off-medication condition (with assessments conducted after medications had been withheld for ≥12 hours) improved by 53% in the neurostimulation group; the betweengroup difference in mean change at 2 years was 16.4 points in favor of neurostimulation (P<0.001). This finding was confirmed by means of blinded assessment of the video recordings of the UPDRS-III score, corroborating the significant improvement among patients in the neurostimulation group, as compared with the medical-therapy group, in which scores did not change (P<0.001) ( Table 2) . A smaller but significant benefit was observed for patients in the neurostimulation group in the on-medication and on-stimulation condition ( Table 2) . UPDRS-IV scores for levodopainduced complications, including motor fluctuations and dyskinesia, improved by 61% in the neurostimulation group, with a 4.1-point difference between treatment groups (P<0.001) ( Table  2) , which was confirmed by the scores on a dyskinesia scale (Table S3 in the Supplementary  Appendix). UPDRS-II scores for activities of daily living in the worst condition during the preceding week differed by 6.2 points in favor of neurostimulation (P<0.001) ( Table 2) , with no significant between-group difference for the score in the best condition. Time with good mobility and no troublesome dyskinesia, as recorded by the patients in daily diaries, increased by 20% in the neurostimulation group, with a between-group difference of 1.9 hours (P = 0.01) ( Table 2) . Time with bad mobility was significantly shortened in the neurostimulation group, with a betweengroup difference of 1.8 hours (P = 0.006) ( Table  S3 in the Supplementary Appendix). Betweengroup differences in time with troublesome dyskinesia and sleep time (Fig. S2 in the Supplementary Appendix) were not significant.
Medication use was significantly changed in both treatment groups. The levodopa-equivalent daily dose was reduced by 39% in the neurostimulation group but was increased by 21% in the medical-therapy group, with a between-group difference of 609 mg (P<0.001) ( Table 2, and  Table S3 in the Supplementary Appendix).
COGNITIVE AND EMOTIONAL OUTCOMES
No significant between-group differences were observed for cognitive assessments obtained with the use of the Mattis Dementia Rating Scale or the UPDRS-I (Table 2) . Changes in mood, as rated by the examiner (score on the Montgomery and Åsberg Depression Rating Scale) or by patients (score on the Beck Depression Inventory II), were in favor of neurostimulation, as were the scores on the Brief Psychiatric Rating Scale for overall psychiatric morbidity. Scores on the Starkstein Apathy Scale worsened in both treatment groups, with a nonsignificant trend toward worse ratings for apathy among patients in the neurostimulation group than among those in the medicaltherapy group (Table 2) .
ADVERSE EVENTS
A total of 68 patients in the neurostimulation group and 56 in the medical-therapy group had at least one serious adverse event. Numbers of all adverse events were similar in the two groups (Table 3, and Table S4 in the Supplementary Appendix). Two patients in the neurostimulation group and 1 in the medical-therapy group committed suicide; these were the only deaths. Suicidal ideation and suicide attempts were of similar frequency in the two groups, but depression was more frequent in the neurostimulation group. Serious adverse events related to motor problems, impulse control disorders, and psychotic manifestations were more common in the medical-therapy group. Of 26 serious adverse events related to surgery or the implanted device, including a brain abscess and a case of unspecific edema, all but 1 resolved completely; the exception was a case of impaired wound healing, which resulted in mild scarring. Unscheduled visits were offered for all health problems; 343 visits occurred in the medical-therapy group and 277 in the neurostimulation group.
ASSESSED CONSISTENCY OF TREATMENT WITH GUIDELINES
Experts assessed medical therapy as consistent with guidelines in 120 patients (96.8%) in the neurostimulation group and in 120 patients (94.5%) in the medical-therapy group. Stimulation parameters at 24 months were similar for both hemispheres, with a mean (±SD) stimulation strength of 2.8±0.7 V, a mean stimulation frequency of 142±27 Hz, and a mean pulse duration of 66±13 μs (pooled data).
DISCUSSION
This patient population with relatively mild parkinsonian motor signs differed from the populations in previous controlled studies of neurostimulation: the mean duration of disease in the patients in our study was only 7.5 years, as compared with 11.1 to 13.8 years 7-10 ; patients were younger (52 years, as compared with 59 to 62 years [8] [9] [10] [11] ); and fluctuations and dyskinesia were present for only 1.7 and 1.5 years, respectively. Nevertheless, patients in the neurostimulation group had a 26% improvement in the PDQ-39 summary index score, corroborating the 24% improvement observed in our pilot study 15 and the 25% improvement observed in our large trial involving patients with advanced Parkinson's disease, 7 in both of which the PDQ-39 summary index score was the primary outcome. The between-group difference in the mean change from baseline of 8.0 points for the PDQ-39 summary index score in favor of neurostimulation is a clinically relevant finding. [33] [34] [35] The profile of improvement in subdomains of quality of life differed slightly from that among patients treated at an advanced stage of the disease, 7 because activity of daily living, emotional well-being, and cognition improved more during this study than during prior studies involving patients with advanced Parkinson's disease. The improvement in the primary outcome was consistent with other measures of quality of life, psychiatric morbidity, and psychosocial function, which all improved in the neurostimulation group, as compared with the medical-therapy group.
Patients received neurostimulation at a stage of the disease when medical treatment is still effective for motor function, as reflected by several findings in the medical-therapy group: the absence of a significant change from baseline in the UPDRS-III motor score and only minimal worsening in the UPDRS-II score for activities of daily living and in the UPDRS-IV score for levodopainduced complications. In addition, diary results for mobility did not change significantly from baseline in the medical-therapy group, but time with bad mobility was reduced and time with good mobility was significantly increased in the neurostimulation group. The observed difference between the treatment groups is thus due to an improvement among patients receiving neurostimulation, as compared with those receiving medical therapy alone, not to deterioration among the latter patients.
Neurostimulation in combination with medical therapy can therefore improve motor symptoms better than medical therapy alone at this earlier stage. Because the levodopa response predicts the extent of the effect of subthalamic stimulation on parkinsonian motor signs, the improvement of the off-medication condition with the use of stimulation was expected. Moreover, in spite of a ceiling effect, the combination of stimulation and medication resulted in a small but significant improvement in the motor score, as compared with medical treatment alone. As a main benefit from the patient's perspective, activities of daily living were improved among patients with neurostimulation in the worst condition during the day, although, as expected, there was no significant difference between groups in the best condition.
Overall, adverse events were more frequent among patients receiving neurostimulation than among those receiving medical therapy only. However, this result was mainly due to a higher number of mild adverse events in the neurostimulation group than in the medical-therapy group. Serious adverse events in the medical-therapy group were more often related to problems of mobility and side effects of medications (hallucinations and behavioral problems), whereas major depression occurred more often among patients with neurostimulation, despite an overall improvement in mood at the end of the trial. The frequency of suicidal behavior, including suicide, was high 36 but did not differ between treatment groups. Although there were three suicides (two in the neurostimulation group and one in the medical-therapy group) as well as four suicide attempts (two in the neurostimulation group and two in the medical-therapy group) during the study, this trial did not suggest that neurostimulation is associated with a higher risk of suicide than medical therapy. Instead, we hypothesize that the decision to eventually undergo neurostimulation may select a specific subgroup of patients with a higher risk for suicidal behavior than the general population. The monitoring procedures established in this study may be useful in the future. A total of 26 serious adverse events were related directly to surgery or the implanted devices; 25 of them resolved completely, and 1 left a cutaneous scar. The strengths of this study include the strict standards for interventions, close monitoring of side effects, the small number of withdrawals, and the consistency between the results of the intention-to-treat and per-protocol analyses. Because standards of medical therapy were well respected in both treatment groups and because motor symptoms and quality of life did not change in the medical-therapy group, the improvement * All adverse events are listed according to the Medical Dictionary for Regulatory Activities, version 14.1. † Worsening of mobility was defined as tremor, rigidity, akinesia, wearing off of medication effect, dystonia, or worsening of symptoms of Parkinson's disease. ‡ Dislocation of device was defined as the dislocation of the stimulator, cable, or lead. § Reoperation was necessary in order to repair the stimulator or lead. ¶ All nonserious adverse events are listed. ‖ Data include moderate, severe, or life-threatening adverse events that were not serious and were reported in at least 10% of the patients in at least one group. These latter adverse events were judged to be life-threatening by the investigator but did not fulfill the criteria for seriousness, which include hospitalization, prolongation of hospitalization, or death. There were nonlethal life-threatening adverse events that did not lead to hospitalization. The remaining moderate, severe, and life-threatening events are reported in detail in Table S4 in the Supplementary Appen dix. A moderate adverse event was defined as one that might interfere with normal activity and lead to the consideration of medical intervention or close followup, and a severe adverse event as an event posing a substantial risk to the patient's health and likely to require medical intervention or close follow-up. Severe adverse events reported here included two life-threatening adverse events that were not judged to fulfill the criteria for seriousness.
among patients who underwent surgical implantation can be attributed to neurostimulation. To overcome the difficulties of blinding in neurostimulation studies, 21 we introduced the blinded review of motor scores with the use of video recordings, which confirmed the superior effect of neurostimulation over medical therapy, supporting the validity of the main study result.
In conclusion, we found that neurostimulation was superior to medical therapy alone at a relatively early stage of Parkinson's disease, before the appearance of severe disabling motor complications. Neurostimulation may be a therapeutic option for patients at an earlier stage than current recommendations suggest. 23 Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.
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